Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit Before October 13 Deadline

Aardvark Therapeutics faces a securities class action alleging that it overstated the safety and development prospects of ARD-101, its treatment candidate for hyperphagia in Prader-Willi syndrome. The company voluntarily paused its Phase 3 HERO trial on February 27, 2026 after reversible cardiac observations at above-target doses, driving shares down more than 56%; the FDA subsequently imposed a full IND clinical hold on May 14, halting all ARD-101 studies and triggering a further 32.1% decline. Investors have until October 13, 2026 to seek appointment as lead plaintiff.

Analysis

This filing is not a new fundamental catalyst: plaintiff-law-firm announcements are typically derivative of already disclosed safety and regulatory events, so the immediate incremental information value is low. The relevant valuation issue is instead whether ARD-101 can return to clinic with a dose restriction, monitoring protocol, or reformulation; until FDA requirements are disclosed, AARD should be valued closer to cash less burn and wind-down risk than on probability-weighted Phase 3 success. The lawsuit can nevertheless increase D&O costs, management distraction, and financing friction at precisely the point when a clinical-stage issuer may need capital to extend runway.

Over the next 1-3 months, the decisive catalyst is FDA correspondence or company disclosure specifying the clinical-hold remediation path. A narrow hold requiring enhanced ECG monitoring could create a sharp short-covering rally, while nonclinical cardiac work, a dedicated QT study, dose-limiting exposure constraints, or a program termination would materially impair both timeline and addressable commercial profile. The key missing inputs are cash runway, quarterly net burn, enrolled-patient disposition, and whether the observed conduction signal is exposure-dependent with an adequate therapeutic window.

The contrarian angle is that the litigation deadline itself should not be traded: lead-plaintiff milestones rarely alter enterprise value. However, depressed liquidity and a single-asset capital structure mean any optimistic language around regulator engagement can create an outsized technical bounce before underlying de-risking occurs; that is a better short-entry setup than chasing weakness after a largely non-incremental legal release. Read-through to PWS-focused peers is limited because this is molecule-specific cardiac safety risk, not evidence against the indication.

Key Decisions for Investors

• No new directional position solely on this legal notice; treat it as non-incremental and wait for FDA remediation details or the next cash-runway disclosure.
• For existing AARD exposure, reduce or hedge into any 20%+ rally driven by litigation resolution speculation or generic FDA-engagement commentary over the next 1-3 months; retain exposure only if management quantifies a viable restart path and post-remediation cash runway exceeds 12 months.
• Tactical short/watch: if AARD rallies materially without disclosed FDA hold conditions, consider a small short with defined risk via puts where liquid. Thesis target is repricing toward net cash if remediation requires a new cardiac study or materially delays Phase 3; invalidate on FDA hold removal with a clearly acceptable dosing and monitoring protocol.
• Set event alerts for quarterly cash burn, going-concern language, an equity/ATM financing announcement, and FDA hold resolution. A financing below market before hold clearance would reinforce downside through dilution and weaken the case for any rebound.